In a press release last month, InSightec, Ltd. reported that pilot clinical trials at four sites have used its MR-guided focused ultrasound system to treat 23 patients with organ confined low risk prostate cancer and that results are promising.
According to InSightec, five patients underwent near total gland ablation that preserved their urinary sphincter and neurovascular bundles, and 18 received focal treatments. None of the procedures (whole gland or focal) triggered Severe Adverse Events during or after treatment, and none required post-treatment intervention, demonstrating a good safety profile.
Company President and CEO Kobi Vortman, PhD said, "We are very encouraged by these early results that give hope that it may be possible in the future to offer prostate cancer patients a treatment option with a lower rate of complications compared to the currently available options."
Participating sites are Sapienza University of Rome in Italy, the National Cancer Centre in Singapore, the NN Petrov Institute of Oncology in St. Petersburg, Russia and the Jaslok Hospital and Research Center in Mumbai, India. InSightec expects to add more study sites in the near future.